Markus Maeurer
Overview
Explore the profile of Markus Maeurer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
199
Citations
5961
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ala A, Touray M, Shafi S, Egan B, Dar O, Essa F, et al.
Lancet
. 2024 Dec;
405(10472):10-13.
PMID: 39647498
No abstract available.
2.
Hui D, Yeboah-Manu D, Nachega J, Rodriguez-Morales A, Traore T, Maeurer M, et al.
Lancet Respir Med
. 2024 Nov;
13(1):11-14.
PMID: 39608386
No abstract available.
3.
Lotze M, Maeurer M, Quezada S, Coukos G
Cancer Discov
. 2024 Aug;
14(8):1366-1368.
PMID: 39091204
Schoenfeld and colleagues report, in this issue, a measurable objective response rate in 6/28 (21.4%) of patients with advanced non-small cell lung cancer treated with lifileucel, a cell therapy product...
4.
Maia A, Tarannum M, Lerias J, Piccinelli S, Borrego L, Maeurer M, et al.
Cells
. 2024 Mar;
13(5.
PMID: 38474415
Natural killer (NK) cells have gained attention as a promising adoptive cell therapy platform for their potential to improve cancer treatments. NK cells offer distinct advantages over T-cells, including major...
5.
da Costa C, Benn C, Nyirenda T, Mpabalwani E, Grewal H, Ahmed R, et al.
Int J Infect Dis
. 2024 Feb;
141S:106987.
PMID: 38417616
Tuberculosis (TB) remains a leading cause of death worldwide and is estimated to have caused 1.3 million deaths worldwide in 2022. Approximately one quarter of the world's population are infected...
6.
7.
Cai Q, Warren S, Pietrobon V, Maeurer M, Qi L, Lu T, et al.
Cancer Cell
. 2023 Sep;
41(10):1689-1695.
PMID: 37714150
Successful implementation of adoptive cell therapy (ACT) of cancer requires comprehensively addressing biological and practical challenges. This approach has been largely overlooked, resulting in a gap between the potential of...
8.
Rodriguez-Morales A, Abbara A, Ntoumi F, Kapata N, Mwaba P, Yeboah-Manu D, et al.
Travel Med Infect Dis
. 2023 Mar;
53:102568.
PMID: 36963477
No abstract available.
9.
Bigenwald C, Haddad Y, Thelemaque C, Carrier A, Birebent R, Ly P, et al.
Oncoimmunology
. 2023 Jan;
12(1):2163785.
PMID: 36632566
The SARS-CoV-2 pandemic still represents a threat for immunosuppressed and hematological malignancy (HM) bearing patients, causing increased morbidity and mortality. Given the low anti-SARSCoV-2 IgG titers post-vaccination, the COVID-19 threat...
10.
Azhar E, Hui D, McCloskey B, El-Kafrawy S, Sharma A, Maeurer M, et al.
Lancet Glob Health
. 2022 Dec;
11(2):e189-e190.
PMID: 36525983
No abstract available.